• 1
    Jordan M, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253265.
  • 2
    Bollag D, McQueney P, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:23252333.
  • 3
    Gradishar W. Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Des Devel Ther 2009;3:163171.
  • 4
    Bystricky B, Chau I. Patupilone in cancer treatment. Expert Opin Investig Drugs 2011;20:107117.
  • 5
    Bocci G, Nicolaou K, Kerbel R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:69386943.
  • 6
    Woltering E, Lewis J, Maxwell P, et al. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann Surg 2003;237:790798; discussion 798-800.
  • 7
    Ferretti S, Allegrini P, O'Reilly T, et al. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 2005;11:77737784.
  • 8
    Fogh S, Machtay M, Werner-Wasik M, et al. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2010;77:10091016.
  • 9
    Freedman R, Bullitt E, Sun L, et al. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer 2011;11:376383.
  • 10
    Rustin G, Reed N, Jayson G, et al. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol 2011;22:24112416.
  • 11
    Stupp R, Tosoni A, Bromberg J, et al. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European organisation for research and treatment of cancer (EORTC) brain tumor group. Ann Oncol 2011;22:21442149.
  • 12
    Dumontet C, Jordan M. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790803.
  • 13
    Momoi Y, Okai Y, Watari T, et al. Establishment and characterization of a canine T-lymphoblastoid cell line derived from malignant lymphoma. Vet Immunol Immunopathol 1997;59:1120.
  • 14
    Fosmire S, Dickerson E, Scott A, et al. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest 2004;84:562572.
  • 15
    Chretin J, Rassnick K, Shaw N, et al. Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: A double-blind, placebo-controlled study. J Vet Intern Med 2007;21:141148.
  • 16
    Le Tourneau C, Lee J, Siu L. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708720.
  • 17
    Vail D. Cancer clinical trials: Development and implementation. Vet Clin North Am Small Anim Pract 2007;37:10331057.
  • 18
    Vail D. Veterinary co-operative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195213.
  • 19
    Vail D, Michels G, Khanna C, et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)–a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol 2010;8:2837.
  • 20
    Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228247.
  • 21
    Crowley E, Callaghan R. Multidrug efflux pumps: Drug binding-gates or cavity? FEBS J 2010;277:530539.
  • 22
    O'Reilly T, Wartmann M, Brueggen J, et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008;62:10451054.
  • 23
    Bley C, Jochum W, Orlowski K, et al. Role of the microenvironment for radiosensitization by patupilone. Clin Cancer Res 2009;15:13351342.
  • 24
    Edelman M. Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin Lung Cancer 2009;10(Suppl 1):S30S34.
  • 25
    Poirier V, Hershey A, Burgess K, et al. Efficacy and toxicity of paclitaxel (taxol) for the treatment of canine malignant tumors. J Vet Intern Med 2004;18:219222.
  • 26
    Simon D, Schoenrock D, Baumgartner W, Nolte I. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med 2006;20:11841190.
  • 27
    Stalder M, Anthony C, Woltering E. Metronomic dosing enhances the anti-angiogenic effect of epothilone B. J Surg Res 2009;169:247256.
  • 28
    Pasquier E, Honore S, Pourroy B, et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005;65:24332440.
  • 29
    Rubin E, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005;23:91209129.
  • 30
    Ten Bokkel Huinink W, Sufliarsky J, Smit W, et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: A phase I, open-label, dose-escalation study. J Clin Oncol 2009;27:30973103.
  • 31
    Kerbel R, Kamen B. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423436.
  • 32
    Hofstetter B, Vuong V, Broggini-Tenzer A, et al. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res 2005;11:15881596.
  • 33
    Rohrer Bley C, Orlowski K, Furmanova P, et al. Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells. Lung Cancer 2011;73:294301.
  • 34
    Argyriou A, Marmiroli P, Cavaletti G, Kalofonos H. Epothilone-induced peripheral neuropathy: A review of current knowledge. J Pain Symptom Manage 2011;42:931940.
  • 35
    Knapp D, Richardson R, Chan T, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273278.
  • 36
    Sorenmo K, Goldschmidt M, Shofer F, et al. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol 2004;2:1323.
  • 37
    Fogh S, Machtay M, Werner-Wasik M, et al. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2010;77:10091016.